WO2008030564A3 - Aglycosylated antibodies and methods of making and using those antibodies - Google Patents

Aglycosylated antibodies and methods of making and using those antibodies Download PDF

Info

Publication number
WO2008030564A3
WO2008030564A3 PCT/US2007/019553 US2007019553W WO2008030564A3 WO 2008030564 A3 WO2008030564 A3 WO 2008030564A3 US 2007019553 W US2007019553 W US 2007019553W WO 2008030564 A3 WO2008030564 A3 WO 2008030564A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
aglycosylated
making
those
Prior art date
Application number
PCT/US2007/019553
Other languages
French (fr)
Other versions
WO2008030564A2 (en
Inventor
Gerald Neslund
Genevieve Hansen
Andrae Stefan
Original Assignee
Verenium Corp
Gerald Neslund
Genevieve Hansen
Andrae Stefan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verenium Corp, Gerald Neslund, Genevieve Hansen, Andrae Stefan filed Critical Verenium Corp
Publication of WO2008030564A2 publication Critical patent/WO2008030564A2/en
Publication of WO2008030564A3 publication Critical patent/WO2008030564A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides methods of preparing aglycosylated antibodies, for instance aglycosylated antibodies with altered or restored effector functions, as well as antibodies prepared by these methods.
PCT/US2007/019553 2006-09-08 2007-09-07 Aglycosylated antibodies and methods of making and using those antibodies WO2008030564A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84343806P 2006-09-08 2006-09-08
US60/843,438 2006-09-08

Publications (2)

Publication Number Publication Date
WO2008030564A2 WO2008030564A2 (en) 2008-03-13
WO2008030564A3 true WO2008030564A3 (en) 2008-09-18

Family

ID=39157866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019553 WO2008030564A2 (en) 2006-09-08 2007-09-07 Aglycosylated antibodies and methods of making and using those antibodies

Country Status (1)

Country Link
WO (1) WO2008030564A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071096B2 (en) 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
US8268972B2 (en) 2008-02-20 2012-09-18 G2 Inflammation Pty Ltd Humanized anti-C5aR antibodies
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
DK2718322T3 (en) 2011-06-06 2018-12-03 Novo Nordisk As THERAPEUTIC ANTIBODIES
CA2976236A1 (en) * 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
EA202090020A1 (en) 2017-07-10 2020-04-28 Интернэшнл - Драг - Дивелопмент - Байотек TREATMENT OF B-CELL MALIGNANT NEW FORMATIONS USING AFUCHOSILED PROPAOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC MEDICINES

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054342A1 (en) * 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation
WO2005018572A2 (en) * 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
WO2006088494A2 (en) * 2004-07-12 2006-08-24 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using the same
WO2007048077A2 (en) * 2005-10-21 2007-04-26 Gtc Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20070231329A1 (en) * 2003-03-03 2007-10-04 Xencor, Inc. Fc Variants Having Increased Affinity for FcyRIIb
WO2007146847A2 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054342A1 (en) * 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20070231329A1 (en) * 2003-03-03 2007-10-04 Xencor, Inc. Fc Variants Having Increased Affinity for FcyRIIb
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation
WO2005018572A2 (en) * 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
WO2006088494A2 (en) * 2004-07-12 2006-08-24 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using the same
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2007048077A2 (en) * 2005-10-21 2007-04-26 Gtc Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
WO2007146847A2 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
LUND J ET AL: "Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 30, no. 8, 1 June 1993 (1993-06-01), pages 741 - 748, XP002325440, ISSN: 0161-5890 *
LUND J ET AL: "Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 1996, vol. 157, no. 11, 1 December 1996 (1996-12-01), pages 4963 - 4969, XP002484003, ISSN: 0022-1767 *
SARMAY G ET AL: "MAPPING AND COMPARISON OF THE INTERACTION SITES ON THE FC REGION OF IGG RESPONSIBLE FOR TRIGGERING ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) THROUGH DIFFERENT TYPES OF HUMAN FCY RECEPTOR", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 29, no. 5, 1 January 1992 (1992-01-01), pages 633 - 639, XP000915240, ISSN: 0161-5890 *
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, AL, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002271092, ISSN: 0021-9258 *
WALKER M R ET AL: "AGLYCOSYLATION OF HUMAN IGG1 AND IGG3 MONOCLONAL ANTIBODIES CAN ELIMINATE RECOGNITION BY HUMAN CELLS EXPRESSING FCGAMMARI AND/OR FCGAMMARII RECEPTORS", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, vol. 259, no. 2, 1 January 1989 (1989-01-01), pages 347 - 353, XP008064058, ISSN: 0264-6021 *
WRIGHT A ET AL: "Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 160, no. 7, 1 April 1998 (1998-04-01), pages 3393 - 3402, XP002443678, ISSN: 0022-1767 *
YAMAGUCHI YOSHIKI ET AL: "Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy.", BIOCHIMICA ET BIOPHYSICA ACTA APR 2006, vol. 1760, no. 4, April 2006 (2006-04-01), pages 693 - 700, XP002484004, ISSN: 0006-3002 *

Also Published As

Publication number Publication date
WO2008030564A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2008034013A3 (en) Medical devices and methods of making the same
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2008091954A3 (en) Optimized cd40 antibodies and methods of using the same
WO2008017962A8 (en) Microcapsules with improved shells
WO2009112245A9 (en) Antibody against the csf-1 r
WO2007093627A3 (en) Biocidal composition
WO2009070243A3 (en) Wise binding antibodies and epitopes
WO2006127757A3 (en) Interferon-igg fusion
WO2007127841A3 (en) Compositions and methods of preparation thereof
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2007120334A3 (en) Methods and compositions for targeting polyubiquitin
WO2007106744A8 (en) Anti-5t4 antibodies and uses thereof
WO2009135181A3 (en) Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2008002893A8 (en) Anti-amyloid antibodies, compositions, methods and uses
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
EP2035398B8 (en) Immobilized 1,2-benzisothiazolin-3-one
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
WO2008021342A3 (en) Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2008025015A3 (en) Epitope-protein scaffolds and their use
WO2008027600A3 (en) Imatinib compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811704

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07811704

Country of ref document: EP

Kind code of ref document: A2